Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus

Translational Stroke Research

Volumn 5, Issue 4, 2014, Pages 510-518

  Kao, Amy H ^a,b   McBurney, Christine A ^c   Sattar, Abdus ^d   Lertratanakul, Apinya ^e   Wilson, Nicole L ^f   Rutman, Sarah ^f   Paul, Barbara ^c   Navratil, Jeannine S ^c   Scioscia, Andrea ^g   Ahearn, Joseph M ^a,b   Manzi, Susan ^a,b,h  

^a ALLEGHENY HEALTH NETWORK   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Complement C4d; Ischemic stroke; Mortality; Platelet; Systemic lupus erythematosus; Vascular event

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; BLOOD; BRAIN ISCHEMIA; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE;

ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; COHORT STUDIES; COMPLEMENT C4B; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; STROKE;

EID: 84885977459     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0295-9     Document Type: Article

References (34)

1. Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54:670–4.
2. Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BFIV, Au K, et al. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke. 2008;39:3236–41.
3. del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201:871–9.
4. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006;177:7266–74.
5. Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, Hassid BG, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res. 2006;99:209–17.
6. Figueroa E, Gordon LE, Feldhoff PW, Lassiter HA. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett. 2005;380:48–53.
7. De Simoni M, Storini C, Barba M, Catapano L, Arabia A, Rossi E, et al. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab. 2003;23:232–9.
8. Salter JW, Krieglstein CF, Issekutz AC, Granger DN. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1432–9.
9. Zhang Z-g, Zhang Q-z, Cheng Y-n, Ji S-l, Du G-h. Antagonistic effects of ultra-low-molecular-weight heparin against cerebral ischemia/reperfusion injury in rats. Pharmacol Res. 2007;56:350–5.
10. Sakurai-Yamashita Y, Kinugawa H, Niwa M. Neuroprotective effect of pentosan polysulphate on ischemia-related neuronal death of the hippocampus. Neurosci Lett. 2006;409:30–4.
11. Kingma JG, Plante S, Bogaty P. Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion. J Am Coll Cardiol. 2000;36:2317–24.
12. Tan E, Cohen A, Fries J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
13. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
14. Liang M, Socher S, Larson M, Schur P. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–18.
15. Bombardier C, Gladman D, Urowitz M, Caron D, Chang C. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.
16. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Rheumatology. 1996;35:248–54.
17. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology. 2009;48:542–5.
18. Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16:309–17.
19. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48:673–5.
20. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen J, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol. 1999;28:75–80.
21. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. European working party on systemic lupus e. morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82:299–308.
22. Tarr T, Gyorfy B, Szekanecz É, Bhattoa HP, Zeher M, Szegedi G, et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:76–82.
23. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol. 2009;23:539–47.
24. Di Napoli M. Systemic complement activation in ischemic stroke. Stroke. 2001;32:1443–8.
25. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137:117–22.
26. Mocco J, Wilson D, Komotar R, Sughrue M, Coates K, Sacco R, et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery. 2006;59:28–33.
27. Imm MD, Feldhoff PW, Feldhoff RC, Lassiter HA. The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats. Neurosci Lett. 2002;325:175–8.
28. Peerschke E, Yin W, Alpert D, Roubey R, Salmon J, Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2009;18:530–8.
29. Lood C, Eriksson S, Gullstrand B, Jönsen A, Sturfelt G, Truedsson L, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus – a possible link to venous thrombosis? Lupus. 2012;21:1423–32.
30. Smyth SS, Mcever RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7:1759–66.
31. Boilard E, Nigrovic PA, Larabee K, Watts GFM, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327:580–3.
32. Spinelli SL, Casey AE, Pollock SJ, Gertz JM, McMillan DH, Narasipura SD, et al. R1: Platelets and megakaryocytes contain functional nuclear factor-{kappa}B. Arterioscler Thromb Vasc Biol. 2010;30(3):591–8.
33. Muhlestein J. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010;103:71–82.
34. Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012;64:4040–7.